Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

OptiNose, Inc.

Initiate a randomized proof-of-concept study of OPN-019

Delivered after the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
3 Mar 2021
Due
30 Apr 2021
Delivered
July 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“In April 2021, the Company expects to initiate a randomized, proof of concept study in subjects who have tested positive for SARS-CoV-2 infection”

What we found

Evidence strength A What the grades mean

The study was not initiated in April 2021. Regulatory approval was still pending in May 2021, and the trial opened for enrollment in July 2021.

  • A
    OptiNose, Inc. 8-K filed 2021-05-05 Regulatory filing · published 5 May 2021 · retrieved 27 Oct 2026 · kept permanently by the SEC
    “Regulatory approval to initiate the pilot study is pending. The Company expects top-line results from this study in second quarter 2021.” ✓ confirmed on the page
  • A
    OptiNose, Inc. 10-Q filed 2021-08-11 Regulatory filing · published 11 Aug 2021 · retrieved 27 Oct 2026 · kept permanently by the SEC
    “In July 2021, we received approval from regulatory authorities in Mexico to proceed with this pilot trial. The trial drug was made available in Mexico in July 2021, and the trial is open for enrollment.” ✓ confirmed on the page
  • A
    OptiNose, Inc. 10-K filed 2022-03-08 Regulatory filing · published 8 Mar 2022 · retrieved 27 Oct 2026 · kept permanently by the SEC
    “In July 2021, we received approval from regulatory authorities in Mexico to conduct a randomized, proof-of-concept trial in Mexico” ✓ confirmed on the page

Checked 27 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical milestone
Indicative materiality
Medium rules
Action
Initiate
Deliverable
Randomized proof-of-concept study of OPN-019
Where
Mexico
Language
Expected (“expects”, “plans”)
In the company’s control
Medium
Specificity
High

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you OptiNose, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C494650-025074 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.